Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-5 of 221 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-5 of 221 studies
-
Genetic TherapyEnrolling
Study to evaluate SPL84 in adults with cystic fibrosis carrying the 3849 + 10 Kb C->T mutation , protocol number SpliSense SPL84-002This study will evaluate the safety, tolerability, effectiveness, and effect on the body of SPL84, an inhaled ASO, in adults with CF carrying the 3849 + 10 Kb C->T mutation.
-
Age:
18 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
13
-
Length of Participation:
115 days
-
-
Restore CFTR ProteinEnrolling
Phase 3 study of VX-121/tezacaftor/deutivacaftor in children ages 2 to 5 with cystic fibrosis , protocol number Vertex VX21-121-105 Cohort B2This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability and how the body processes the drug VX-121/tezacaftor/deutivacaftor in participants with at least one triple-combination responsive CF mutation.
-
Age:
2 Years to 5 Years
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
8
-
Length of Participation:
32 weeks
-
-
Anti-InfectiveEnrolling
ABATE: Study to evaluate IV gallium in adults with cystic fibrosis who have nontuberculous mycobacteria (NTM) , protocol number ABATE-IP-18-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25% or greater
-
Number of Visits:
8
-
Length of Participation:
20 weeks
-
-
ObservationalEnrolling
Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part B) , protocol number BEGIN-OB-19 Part BThis two-part observational study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.
-
Age:
Less than 6 Years
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
9
-
Length of Participation:
5 years
-
-
OtherEnrolling
A study to evaluate the insulin-only Bionic Pancreas in people with cystic fibrosis 14 years of age or older who have cystic fibrosis-related diabetes (CFRD) , protocol number Bionic Pancreas CFRD IOBP V 1.0.This study will evaluate the effectiveness and safety of using the insulin-only Bionic Pancreas (BP) system compared to using one’s usual insulin delivery method.
-
Age:
14 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
4
-
Length of Participation:
7 months
-
Showing 1-5 of 221 studies
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More